We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Role of the ACV
The ACV provides independent medical and scientific advice to the Minister for Health and the Therapeutic Goods Administration (TGA) on issues relating to the safety, quality and efficacy of vaccines supplied in Australia including issues relating to pre-market assessment, post-market monitoring and safe use in national immunisation programs.
The Committee is established under Regulation 39F of the Therapeutic Goods Regulations 1990 and the members are appointed by the Minister for Health.
The ACV was established in January 2017, following consolidation of previous functions of the Advisory Committee on the Safety of Vaccines (ACSOV) and the pre-market functions for vaccines of the Advisory Committee on Prescription Medicines (ACPM).
Membership comprises professionals with expertise in specific scientific, medical or clinical fields, or consumer health issues.
Membership
The current membership of the committee is available on our ACV members page.
2024 ACV proposed meeting dates
| Meeting no. | Meeting dates |
|---|---|
| ACV 47 | 31 January 2024 |
| ACV 48 | 1 May 2024 |
| ACV 49 | 2 October 2024 |
| ACV 50 | 4 December 2024 |
Contact details for the ACV
| ACV enquiries | Committee support enquiries | |
|---|---|---|
| acv@health.gov.au | Committees@health.gov.au | |
| Postal Address | Advisory Committee on Vaccines Therapeutic Goods Administration PO Box 100 WODEN ACT 2606 Attn: Prescription Medicines Authorisation Branch, MDP 122 | Committee Support Unit Therapeutic Goods Administration PO Box 100 WODEN ACT 2606 Attn: Collaboration Services Section, MDP 122 |